BCAM and cervical cancer: In this study, the susceptibility of human cervical cancer cells to BCA-M has been tested and compared to another L-arginine depletion drug—L-arginine deiminase (ADI, undergoing Phase III clinical trial [21])—which converts L-arginine into L-citrulline and ammonia.